This is not the most recent version of the article. View current version (29 SEP 2014)

Intervention Protocol

You have free access to this content

Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity

  1. Noortje van Herwaarden1,*,
  2. Alfons Den Broeder1,
  3. Wilco Jacobs2,
  4. Johannes WJ Bijlsma3,
  5. Ronald F Van Vollenhoven4,
  6. Bart(holomeus) JF Van den Bemt5

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010455


How to Cite

van Herwaarden N, Den Broeder A, Jacobs W, Bijlsma JWJ, Van Vollenhoven RF, Van den Bemt BJF. Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010455. DOI: 10.1002/14651858.CD010455.

Author Information

  1. 1

    Sint Maartenskliniek, Department of Rheumatology, Nijmegen, Gelderland, Netherlands

  2. 2

    Leiden University Medical Center, Department of Neurosurgery, Leiden, Netherlands

  3. 3

    University Medical Center Utrecht, Rheumatology & Clinical Immunology, Utrecht, Netherlands

  4. 4

    The Karolinska Institute, Department of Medicine, Stokholm, Stokholm, Sweden

  5. 5

    Sint Maartenskliniek, Department of Pharmacy, Nijmegen, Gelderland, Netherlands

*Noortje van Herwaarden, Department of Rheumatology, Sint Maartenskliniek, Hengstdal 3, Nijmegen, Gelderland, 6522 JV, Netherlands. N.vanHerwaarden@maartenskliniek.nl.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (29 SEP 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefits and harms on disease activity, functioning, costs, safety and radiographic damage of down titration (dose reduction, interval increase or discontinuation) of tumor necrosis factor blocking (anti-TNF) agents (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) compared with usual care in patients with rheumatoid arthritis (RA) and low disease activity.